Fate can be altered

Discovering and developing first-in-class small molecule drugs for improved treatment of diseases with significant clinical need.

More info More info


To become a leading biotechnology company, globally recognized for discovering and developing breakthrough small molecule drugs acting on novel RNA and unexplored protein targets

More info More info


Molecure’s exceptional in-house medicinal chemistry, biology and discovery capabilities allied to novel target biology gained from leading universities worldwide has enabled us to create a broad pipeline of drug candidates targeting unique and unexplored protein targets, as well as a cutting-edge small molecule mRNA targeting discovery platform.

Discover our pipeline Discover our pipeline


On the 28th March 2022, OncoArendi changed its name to Molecure

Molecure to begin clinical development of novel dual arginase inhibitor OATD-02 for the treatment of cancer after gaining permission to conduct first clinical trial in Poland

28 November 2022

Molecure to Host Virtual R&D Day on 7th December 2022

14 November 2022

Molecure Third Quarter 2022 Pipeline Highlights and Financial Results

31 October 2022

Join us

People are the foundation of Molecure’s success. Our scientists are the creators of the best ideas for the multiple new small molecule medicines that are invented in the laboratories. The Molecure team works together to discover the therapies needed to improve the treatment of previously incurable diseases.
It is this unified goal that guides us every day. We are inspired by science, we discover and create. For us, work is a passion.

More info More info
This site is registered on wpml.org as a development site.